Search clinical trials for: mTOR Inhibitor

Total 68124 results

Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Hepatocellular Carcinoma | Solid Tumor, Adult

China
National Cancer Institute (NCI)

Recruiting

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Locally Advanced Lung Neuroendocrine Neoplasm | Lung Neuroendocrine Neoplasm | Metastatic Lung Neuroendocrine Neoplasm | Recurrent Lung Neuroendocrine Neoplasm | Unresectable Lung Neuroendocrine Neoplasm | Advanced Lung Neuroendocrine Tumor | Functioning Lung Neuroendocrine Tumor | Lung Neuroendocrine... and other conditions

United States
Instituto Nacional de Cardiologia Ignacio Chavez

Recruiting

Randomized Trial Comparing Two Sirolimus-Eluting Stents in Diabetes Mellitus (INC-DM)

Coronary Artery Disease | Diabetes Mellitus | Acute Coronary Syndrome

Mexico
King Chulalongkorn Memorial Hospital

Recruiting

The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus in Treatment of BK Virus Infection in Kidney Transplantation Recipient (ELF)

BK Virus Infection | Kidney Transplant Infection

Thailand
University of California, San Francisco
Novartis Pharmaceuticals; Pediatric Brain Tumor Foundation; The Lilabean Foundation...

Recruiting

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

High Grade Glioma | Low-grade Glioma | Recurrent World Health Organization (WHO) Grade II Glioma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Not yet recruiting

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Metastatic Sarcoma | Resectable Sarcoma | Recurrent Sarcoma

United States
Amgen

Recruiting

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Advanced Solid Tumors | Kirsten Rat Sarcoma (KRAS) pG12C Mutation

United States, Italy, Taiwan, Spain, United Kingdom, Australia, Austria, Germany, Belgium, Japan, Netherlands, Korea, Republic of, Canada
Uppsala University Hospital

Recruiting

A MolEcularly Guided Anti-Cancer Drug Off-Label Trial (MEGALiT)

Solid Tumor

Sweden
Mats Remberger
The Swedish Research Council

Recruiting

Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT (2017-00355)

GVHD, Acute

Sweden, Norway, Denmark
Peking University International Hospital

Recruiting

Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis

Retroperitoneal Fibrosis

China
Hospices Civils de Lyon

Recruiting

Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection (STARR)

Kidney Transplant Failure and Rejection

France
Fudan University

Recruiting

FUSCC Refractory TNBC Umbrella (FUTURE) (FUTURE)

Triple-negative Breast Cancer

China
Canadian Cancer Trials Group
Bristol-Myers Squibb; Pfizer; Hoffmann-La Roche; AstraZeneca; Seagen Inc.

Recruiting

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR)

Lymphoma, Non-Hodgkin | Multiple Myeloma | Advanced Solid Tumors

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

Metastatic Malignant Neoplasm in the Liver | Advanced Malignant Neoplasm | Refractory Malignant Neoplasm | Colorectal Carcinoma Metastatic in the Liver

United States
Dana-Farber Cancer Institute
Pfizer

Recruiting

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Pancreatic Cancer | Solid Tumors | Lung Cancer Squamous Cell | Head & Neck Cancer

United States
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Recruiting

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART)

Pediatric Cancer

Italy, France, Denmark, Germany, Netherlands, Spain, United Kingdom
American Society of Clinical Oncology
Bristol-Myers Squibb; Eli Lilly and Company; Bayer; Merck Sharp & Dohme LLC; Pfizer; AstraZene... and other collaborators

Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)

Lymphoma, Non-Hodgkin | Multiple Myeloma | Advanced Solid Tumors

United States
University of Cincinnati
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaborators

Recruiting

Safety and Durability of Sirolimus for Treatment of LAM (MIDAS)

Lymphangioleiomyomatosis

United States
Royal Marsden NHS Foundation Trust
Institute of Cancer Research, United Kingdom; Verastem, Inc.; Chugai Pharmaceutical

Recruiting

Phase I Trial of VS-6766 Alone and in Combination With Everolimus (RAF/MEK)

Multiple Myeloma | Ovarian Cancer | Lung Cancer | Solid Tumours

United Kingdom
Centre Leon Berard
National Cancer Institute, France

Recruiting

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (MOST plus)

Malignant Solid Neoplasms

France
Eisai Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (CLEAR)

Renal Cell Carcinoma

Korea, Republic of, Spain, United States, Netherlands, Ireland, Canada, United Kingdom, Poland, Italy, Australia, Russian Federation, Belgium, Israel, France, Greece, Czechia, Switzerland, Austria, Germany, Japan
M.D. Anderson Cancer Center

Active, not recruiting

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

Advanced Cancer

United States
Dana-Farber Cancer Institute
Regeneron Pharmaceuticals

Active, not recruiting

Cemiplimab in AlloSCT/SOT Recipients With CSCC (CONTRAC)

Advanced Cancer | Cutaneous Squamous Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

Neuroendocrine Neoplasm | Multiple Endocrine Neoplasia Type 1 | Advanced Carcinoid Tumor | Digestive System Neuroendocrine Neoplasm | Unresectable Carcinoid Tumor

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | ROS1 Gene Rearrangement | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | ALK Positive

United States
Aadi Bioscience, Inc.

Active, not recruiting

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Malignant Solid Neoplasm | Neoplasms | Cancer | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Metastasis | Advanced Solid Tumor | Metastatic Solid Tumor | Advanced Cancer | Tumor | Malignant Neoplasm | Malignant Tumor | Tumors | Cancer Metastatic | Tumor, Solid | Malignant Solid Tumor | TSC | TSC1 | TSC2 | Metastatic Neoplasm

United States, Korea, Republic of, Puerto Rico
Eli Lilly and Company

Active, not recruiting

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Endometrial Cancer

United States, Spain, France, Belgium, Taiwan, Australia, Korea, Republic of, Japan
Boston Scientific Corporation

Active, not recruiting

PROMUS PREMIER™ China Post-Approval Study

Coronary Artery Disease

China
National Cancer Institute (NCI)

Active, not recruiting

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

PRETEXT I Hepatoblastoma | PRETEXT II Hepatoblastoma | PRETEXT III Hepatoblastoma | PRETEXT IV Hepatoblastoma

United States, Canada, Puerto Rico, Australia, Japan, Brazil
M.D. Anderson Cancer Center

Active, not recruiting

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

Advanced Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Recurrent Uterine Corpus Cancer | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine Corpus Cancer... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Novartis

Active, not recruiting

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

Endometrial Cancer

United States
Novartis Pharmaceuticals

Active, not recruiting

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Tuberous Sclerosis Complex

United States, Spain, Belgium, Taiwan, Turkey, Australia, Korea, Republic of, Thailand, France, Hungary, United Kingdom, Italy, Japan, Canada, Russian Federation, Poland, Mexico, Colombia
Novartis Pharmaceuticals

Active, not recruiting

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Carcinoma, Renal Cell

Spain, Singapore, Czechia, Italy, Japan, France, United States
St. Joseph's Hospital and Medical Center, Phoenix
Barrow Neurological Institute; Ivy Brain Tumor Center

Completed

A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

Glioblastoma Multiforme | Glioma of Brain

United States
University of Texas Southwestern Medical Center

Completed

Everolimus for Children With Recurrent or Progressive Ependymoma

Recurrent Childhood Ependymoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Temsirolimus in Combination With Metformin in Patients With Advanced Cancers

Advanced Cancers

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | KRAS Gene Mutation | Metastatic Malignant Solid Neoplasm | EGFR Gene Mutation | ERBB2 Gene Amplification | ERBB2 Gene Mutation | EGFR Gene Amplification | ERBB3 Gene Mutation | ERBB4 Gene Mutation

United States
RayzeBio, Inc.

Active, not recruiting

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1)

Neuroendocrine Tumors | Carcinoid Tumor | Gastroenteropancreatic Neuroendocrine Tumor | Carcinoid | GEP-NET | Gastroenteropancreatic Neuroendocrine Tumor Disease | Pancreatic NET

Canada, Spain, United States, Netherlands, Belgium, France, Brazil
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Castleman Disease | Lymphangioleiomyomatosis | Digestive System Carcinoma | Malignant Neoplasm | Recurrent Breast Carcinoma | Recurrent Thyroid Gland Carcinoma | Metastatic Urothelial Carcinoma | Malignant Female Reproductive System Neoplasm | Neurofibromatosis Type 2 | Recurrent Adult Soft Tissue Sarcoma and other conditions

United States
National Institute of Allergy and Infectious Diseases...
PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)

Terminated

Liver Transplantation With Tregs at UCSF (LITTMUS-UCSF)

Liver Transplant

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Rhabdomyosarcoma | Alveolar Rhabdomyosarcoma | Embryonal Rhabdomyosarcoma | Botryoid-Type Embryonal Rhabdomyosarcoma | Sclerosing Rhabdomyosarcoma | Spindle Cell Rhabdomyosarcoma

United States, Canada, Puerto Rico, Australia, New Zealand
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Carcinoma, Renal Cell

Hungary, United States, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Hong Kong, Italy, Japan, Korea, Republic of, Norway, Russian Federation, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom
Yousef Zakharia
Eisai Inc.

Active, not recruiting

Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma

United States
UNICANCER
Ministry of Health, France

Active, not recruiting

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

Primary Non-metastatic Breast Cancer | Who Remain Disease-free

France
Ohio State University
Pfizer; PTEN Research

Active, not recruiting

Sirolimus for Cowden Syndrome With Colon Polyposis

Cowden Syndrome | Polyposis | PTEN Gene Mutation | PTEN Hamartoma Tumor Syndrome | PTEN Hamartoma Syndrome | Bannayan Syndrome | Bannayan Zonana Syndrome

United States
Abbott Medical Devices

Completed

XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE PRIME SV Japan PMS)

Myocardial Ischemia | Coronary Artery Disease | Angina Pectoris | Ischemic Heart Disease | Coronary Artery Occlusion

Japan
M.D. Anderson Cancer Center
Novartis

Active, not recruiting

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

Endometrial Cancer

United States
M.D. Anderson Cancer Center

Active, not recruiting

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

Recurrent Endometrial Carcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Refractory Endometrial Carcinoma | Refractory... and other conditions

United States

Search clinical trials for: mTOR Inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations